Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_assertion type Assertion NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_head.
- NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_provenance.
- NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_assertion evidence source_evidence_literature NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_provenance.
- NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_assertion SIO_000772 9767613 NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_provenance.
- NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_assertion wasDerivedFrom befree-2016 NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_provenance.
- NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_assertion wasGeneratedBy ECO_0000203 NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_provenance.